Magazine Article | November 1, 2022

Cashing In On Collaboration

Source: Life Science Leader

By Matthew Pillar, Editor, Bioprocess Online

How does a biopharma business that’s potentially years away from its first shot at therapeutic sales revenue thrive in a high-inflation, high-interest, supply-constrained business environment?

It might do well to study the playbook of a more innovative peer. Episode 103 of the “Business of Biotech” podcast offers a case in point. Our conversation with Philogen CEO, CSO, and cofounder Prof. Dario Neri, Ph.D. reveals his company’s metered emergence from academia, its avoidance of venture capital, and its rapid realization of revenue through pre-pipeline collaboration.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader